Literature DB >> 1650915

New antiviral strategy using capsid-nuclease fusion proteins.

G Natsoulis1, J D Boeke.   

Abstract

Overexpression of dominant-negative mutants of various viral proteins can result in 'intracellular immunization'. Here we describe a new approach to interfering with viral replication in which a nuclease is fused to a capsid component so that the nuclease is encapsidated inside the virion where it can inactivate viral nucleic acid. We used Ty1, a yeast retrotransposon whose transposition closely parallels retroviral replication mechanisms and serves as an easily manipulated model for the retroviral infection process. We constructed fusion genes consisting of the region encoding the N-terminal portion of the TYA/TYB open reading frames of retrotransposon Ty1 and either of two different nuclease genes. Ty1-nuclease fusion proteins are targeted to Ty1 virus-like particles, and are active in degrading nucleic acids. A Ty1-barnase fusion protein causes 98-99% reduction in the efficiency of Ty1 transposition in vivo, presumably by degrading encapsidated Ty1 RNA. This strategy, referred to as capsid-targeted viral inactivation, may be useful for interfering with the replication of retroviruses and other viruses.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1650915     DOI: 10.1038/352632a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  22 in total

1.  Using molecular beacons as a sensitive fluorescence assay for enzymatic cleavage of single-stranded DNA.

Authors:  J J Li; R Geyer; W Tan
Journal:  Nucleic Acids Res       Date:  2000-06-01       Impact factor: 16.971

2.  Quantifying anti-HBV effect of targeted ribonuclease by real-time fluorescent PCR.

Authors:  Jun Liu; Ying-Hui Li; Jin Ding; Wei-Dong Gong; Cai-Fang Xue; Ya Zhao; Yu-Xiao Huang
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

3.  Therapeutic effect of a Gag-nuclease fusion protein against retroviral infection in vivo.

Authors:  G Schumann; M Hermankova; K Cannon; J L Mankowski; J D Boeke
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Development of a novel anti-HIV-1 agent from within: effect of chimeric Vpr-containing protease cleavage site residues on virus replication.

Authors:  D Serio; T A Rizvi; M Cartas; V S Kalyanaraman; I T Weber; H Koprowski; A Srinivasan
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

5.  Expression of functional hepatitis B virus polymerase in yeast reveals it to be the sole viral protein required for correct initiation of reverse transcription.

Authors:  J E Tavis; D Ganem
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

6.  Mapping the multimerization domains of the Gag protein of yeast retrotransposon Ty1.

Authors:  C B Brachmann; J D Boeke
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

7.  Targeting of a nuclease to murine leukemia virus capsids inhibits viral multiplication.

Authors:  G Natsoulis; P Seshaiah; M J Federspiel; A Rein; S H Hughes; J D Boeke
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-17       Impact factor: 11.205

8.  A virion-specific inhibitory molecule with therapeutic potential for human immunodeficiency virus type 1.

Authors:  Z Matsuda; X Yu; Q C Yu; T H Lee; M Essex
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

9.  Targeted ribonuclease can inhibit replication of hepatitis B virus.

Authors:  Jun Liu; Ying-Hui Li; Cai-Fang Xue; Jin Ding; Wei-Dong Gong; Ya Zhao; Yu-Xiao Huang
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

10.  Inhibition of HBV targeted ribonuclease enhanced by introduction of linker.

Authors:  Wei-Dong Gong; Jun Liu; Jin Ding; Ya Zhao; Ying-Hui Li; Cai-Fang Xue
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.